ArticleNature cancer2025

Author Correction: Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial.

Won Seog Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.